title: Central administration of zinc increases renal sodium and potassium excretion in rats.
abstract: The aim of the present study was to investigate the effect of acute third ventricle injections of zinc on the brain control of renal sodium and potassium excretion. Adult Wistar male rats received third ventricle injections of zinc acetate in three different doses (0.03, 0.3 and 3.0 nmol/rat). Third ventricle administration of zinc acetate provoked a significant intensification of natriuresis and kaliuresis as compared to sodium acetate-treated controls. When rats were pretreated with losartan, a selective angiotensin II AT1 receptor antagonist (10.8 nmol/rat into the third ventricle 10 min before central zinc injection) the increase in both natriuresis and kaliuresis was abolished. Furthermore, pretreatment with gadolinium, a calcium channel blocker (0.3 nmol/rat into the third ventricle 20 min before central zinc injection), also blunted the increase in renal sodium and potassium excretion seen in animals receiving zinc alone. In a group of rats receiving the same water load used in the previous experiments, the injection of zinc acetate into the third ventricle (3.0 nmol/rat) did not modify arterial blood pressure. It is suggested that zinc in the central nervous system may be involved in the control of renal sodium and potassium excretion by a mechanism unrelated to blood pressure increase. It is also shown that both natriuretic and kaliuretic actions of zinc depend on AT1 receptor activation. Whatever should be the mechanism(s) related to the central effects of zinc here evidenced, the functional integrity of calcium channels is required.
authors.affiliation: Department of Physiology, Health Sciences Institute, Federal University of Bahia, 40110-100, Salvador, BA, Brazil.
authors.forename: E
authors.initials: E
authors.lastname: De Castro-e-Silva
authors.forename: C P
authors.initials: CP
authors.lastname: Luz
authors.forename: C A
authors.initials: CA
authors.lastname: Marinho
authors.forename: L
authors.initials: L
authors.lastname: Castro
authors.forename: C
authors.initials: C
authors.lastname: Sarmento
authors.forename: V
authors.initials: V
authors.lastname: Gonzalez
authors.forename: P
authors.initials: P
authors.lastname: Oliveira
authors.forename: T
authors.initials: T
authors.lastname: Nascimento
authors.forename: P
authors.initials: P
authors.lastname: Santana
authors.forename: A K
authors.initials: AK
authors.lastname: Lima
authors.forename: J B
authors.initials: JB
authors.lastname: Fregoneze
mesh_terms: D000804:Angiotensin II / Q000502:physiology; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001923:Brain Chemistry / Q000502:physiology; D015220:Calcium Channels / Q000502:physiology; D005682:Gadolinium / Q000494:pharmacology; D007276:Injections, Intraventricular; D007668:Kidney / Q000294:innervation / Q000502:physiology; D019808:Losartan / Q000494:pharmacology; D008297:Male; D011188:Potassium / Q000652:urine*; D051381:Rats; D017208:Rats, Wistar; D012964:Sodium / Q000652:urine*; D020542:Third Ventricle; D014554:Urination / Q000187:drug effects; D014882:Water-Electrolyte Balance / Q000187:drug effects*; D015032:Zinc / Q000494:pharmacology*
chemical_list: D000959:Antihypertensive Agents; D015220:Calcium Channels; D000804:Angiotensin II; D012964:Sodium; D005682:Gadolinium; D015032:Zinc; D019808:Losartan; D011188:Potassium